Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly Receives European Approval For Alimta
Eli Lilly has received the European Commission approval for the use of Alimta (pemetrexed for injection) as monotherapy. It is for maintenance treatment of patients with other than
Eli Lilly has received the European Commission approval for the use of Alimta (pemetrexed for injection) as monotherapy. It is for maintenance treatment of patients with other than
InNexus and Genhelix have signed a Letter of Intent to set the stage for a planned strategic collaboration, to focus on developing novel antibodies engineered with InNexus’ DXL
Medtronic has initiated a recall of specific lots of Quick-set infusion sets that are used with MiniMed Paradigm insulin pumps. Affected infusion sets are reference numbers MMT-396, MMT-397,
EpiCept has initiated post-approval clinical study with Ceplene (histamine dihydrochloride), following Ethics Committee and Competent Authority approvals in Sweden, Belgium, and France. The company said that the study
Mentor Capital has acquired 20% stake in Quantum Immunologics, where Mentor Capital will provide equity funding to support Quantum Immunologics (QI) to complete the Phase I/II trials on
Cardinal Health board of directors has approved the spinoff of CareFusion through a pro rata distribution of at least 80% of the shares of CareFusion common stock to
Amarillo has completed the enrollment procedure in a Phase 2 clinical study of the oral interferon product at the University of Western Australia. The company said that a
Addex, in an exclusive collaboration and license agreement with Merck & Co., has achieved the second preclinical milestone. The collaboration is focused on developing an emerging type of
Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin in the US, with an option for global rights. Urocidin is a patented formulation of
Aurobindo Pharma has received final approval for Fosinopril Sodium and Hydrochlorothiazide Tablets (USP 10/12.5mg and 20/12.5mg) from the FDA. Fosinopril Sodium and Hydrochlorothiazide Tablets USP 10/12.5mg and 20/12.5mg